Kirkland Advises Danaher Corporation on Sale of Certain Businesses to Sartorius AG as Part of the GE Biopharma Acquisition Regulatory Process

Kirkland & Ellis represents Danaher Corporation (NYSE: DHR), which today announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, microcarriers and particle validation standards businesses to Sartorius AG for approximately $750 million. Danaher entered into the sale of these businesses as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business, and the closing of the Sartorius AG agreement is conditioned upon Danaher’s closing its acquisition of the GE Biopharma business. Danaher’s acquisition of the GE Biopharma business, the proposed regulatory remedies (the package of businesses being sold), the approval of Sartorius as the buyer in such remedies, and Sartorius’ acquisition described above all remain subject to approvals from various regulatory authorities.

Read the company press release

The Kirkland team is led by transactional partners Michael Brueck, James Hu and Francisco Morales, and included partner Daniel Wolf.